Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effects on lipid metabolism


Autoria(s): Falbo Guazzelli, Cristina Aparecida; Barreiros, Fernando Augusto; Barbosa, Ricardo; Torloni, Maria Regina; Barbieri, Marcia
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

Background: Combined oral contraceptives used in an extended regimen have been studied because of their potential benefits; however, there have been few publications on extended regimens of contraceptive vaginal rings. The aim of this study was to assess the effects of these two extended regimens on the lipid metabolism of women using these contraceptive methods during 1 year. Study Design: This prospective study enrolled 150 women: 75 used a vaginal contraceptive ring (11.7 mg etonogestrel and 2.7 mg ethinyl estradiol), and 75 used oral contraceptives (30 mcg ethinyl estradiol and 150 mg desogestrel). Both groups used their respective method for 84 days followed by a 7-day pause during I year. At baseline and every 3 months during the study period, blood was collected to assess total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and apolipoprotein (apo) A-I and B. The analysis of variance test was used to analyze differences in the results of these exams over time. Results: A total of 62 vaginal ring and 61 oral contraceptive users completed the study. There were no significant differences in the discontinuation rate, mean total cholesterol and fraction levels, apo B concentration or apo A-I/apo B ratio. Vaginal ring users had significantly higher apo A-I levels than oral contraceptive users. Conclusion: Despite the vaginal route of administration, the steroids released by the ring had the same effects on the lipid metabolism and lipoprotein levels typically seen with ethinyl estradiol given either by oral or parenteral routes. (C) 2012 Elsevier Inc. All rights reserved.

Identificador

CONTRACEPTION, NEW YORK, v. 85, n. 4, supl., Part 3, pp. 389-393, APR, 2012

0010-7824

http://www.producao.usp.br/handle/BDPI/41154

10.1016/j.contraception.2011.08.014

http://dx.doi.org/10.1016/j.contraception.2011.08.014

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE INC

NEW YORK

Relação

CONTRACEPTION

Direitos

closedAccess

Copyright ELSEVIER SCIENCE INC

Palavras-Chave #HORMONAL CONTRACEPTIVE #LIPIDS-CHOLESTEROL #HORMONAL METABOLIC #CONTRACEPTIVE VAGINAL #EXTENDED CYCLE #DENSITY-LIPOPROTEIN CHOLESTEROL #CORONARY-HEART-DISEASE #APOLIPOPROTEIN-A-I #30 MU-G #ETHINYL ESTRADIOL #CARDIOVASCULAR-DISEASE #CARBOHYDRATE-METABOLISM #DESOGESTREL #RISK #PLASMA #OBSTETRICS & GYNECOLOGY
Tipo

article

original article

publishedVersion